已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

CHIVA method for the treatment of chronic venous insufficiency

医学 静脉曲张 慢性静脉功能不全 随机对照试验 回廊的 奇纳 梅德林 置信区间 相对风险 荟萃分析 物理疗法 外科 重症监护医学 内科学 心理干预 法学 精神科 政治学
作者
Sergi Bellmunt-Montoya,J.M. Escribano-Ferrer,Percy Efrain Pantoja,Cristina Tello-Díaz,María José Martínez‐Zapata
出处
期刊:The Cochrane library [Elsevier]
卷期号:2021 (9) 被引量:43
标识
DOI:10.1002/14651858.cd009648.pub4
摘要

Many surgical approaches are available to treat varicose veins secondary to chronic venous insufficiency. One of the least invasive techniques is the ambulatory conservative hemodynamic correction of venous insufficiency method (in French 'cure conservatrice et hémodynamique de l'insuffisance veineuse en ambulatoire' (CHIVA)), an approach based on venous hemodynamics with deliberate preservation of the superficial venous system. This is the second update of the review first published in 2013.To compare the efficacy and safety of the CHIVA method with alternative therapeutic techniques to treat varicose veins.The Cochrane Vascular Information Specialist searched the Cochrane Vascular Specialised Register, CENTRAL, MEDLINE, Embase, CINAHL, AMED, and the World Health Organisation International Clinical Trials Registry Platform and ClinicalTrials.gov trials registries to 19 October 2020. We also searched PUBMED to 19 October 2020 and checked the references of relevant articles to identify additional studies.We included randomized controlled trials (RCTs) that compared CHIVA to other therapeutic techniques to treat varicose veins.Two review authors independently assessed and selected studies, extracted data, and performed quantitative analysis from the selected papers. A third author solved any disagreements. We assessed the risk of bias in included trials with the Cochrane risk of bias tool. We calculated the risk ratio (RR), mean difference (MD), number of people needed to treat for an additional beneficial outcome (NNTB), and the number of people needed to treat for an additional harmful outcome (NNTH), with 95% confidence intervals (CI). We evaluated the certainty of the evidence using GRADE. The main outcomes of interest were the recurrence of varicose veins and side effects.For this update, we identified two new additional studies. In total, we included six RCTs with 1160 participants (62% women) and collected from them eight comparisons. Three RCTs compared CHIVA with vein stripping. One RCT compared CHIVA with compression dressings in people with venous ulcers. The new studies included three comparisons, one compared CHIVA with vein stripping and radiofrequency ablation (RFA), and one compared CHIVA with vein stripping and endovenous laser therapy. We judged the certainty of the evidence for our outcomes as low to very low due to inconsistency, imprecision caused by the low number of events and risk of bias. The overall risk of bias across studies was high because neither participants nor personnel were blinded to the interventions. Two studies attempted to blind outcome assessors, but the characteristics of the surgery limited concealment. Five studies reported the outcome clinical recurrence of varicose veins with a follow-up of 18 months to 10 years. CHIVA may make little or no difference to the recurrence of varicose veins in the lower limb compared to stripping (RR 0.74, 95% CI 0.46 to 1.20; 5 studies, 966 participants; low-certainty evidence). We are uncertain whether CHIVA reduced recurrence compared to compression dressing (RR 0.23, 95% CI 0.06 to 0.96; 1 study, 47 participants; very low-certainty evidence). CHIVA may make little or no difference to clinical recurrence compared to RFA (RR 2.02, 95% CI 0.74 to 5.53; 1 study, 146 participants; low-certainty evidence) and endovenous laser (RR 0.20, 95% CI 0.01 to 4.06; 1 study, 100 participants; low-certainty evidence). We found no clear difference between CHIVA and stripping for the side effects of limb infection (RR 0.83, 95% CI 0.33 to 2.10; 3 studies, 746 participants; low-certainty evidence), and superficial vein thrombosis (RR 1.05, 95% CI 0.51 to 2.17; 4 studies, 846 participants; low-certainty evidence). CHIVA may reduce slightly nerve injury (RR 0.14, 95% CI 0.02 to 0.98; NNTH 9, 95% CI 5 to 100; 4 studies, 846 participants; low-certainty evidence) and hematoma compared to stripping (RR 0.59, 95% CI 0.37 to 0.97; NNTH 11, 95% CI 5 to 100; 2 studies, 245 participants; low-certainty evidence). For bruising, one study found no differences between groups while another study found reduced rates of bruising in the CHIVA group compared to the stripping group. Compared to RFA, CHIVA may make little or no difference to rates of limb infection, superficial vein thrombosis, nerve injury or hematoma, but may cause more bruising (RR 1.15, 95% CI 1.04 to 1.28; NNTH 8, CI 95% 5 to 25; 1 study, 144 participants; low-certainty evidence). Compared to endovenous laser, CHIVA may make little or no difference to rates of limb infection, superficial vein thrombosis, nerve injury or hematoma. The study comparing CHIVA versus compression did not report side effects.There may be little or no difference in the recurrence of varicose veins when comparing CHIVA to stripping (low-certainty evidence), but CHIVA may slightly reduce nerve injury and hematoma in the lower limb (low-certainty evidence). Very limited evidence means we are uncertain of any differences in recurrence when comparing CHIVA with compression (very low-certainty evidence). CHIVA may make little or no difference to recurrence compared to RFA (low-certainty evidence), but may result in more bruising (low-certainty evidence). CHIVA may make little or no difference to recurrence and side effects compared to endovenous laser therapy (low-certainty evidence). However, we based these conclusions on a small number of trials with a high risk of bias as the effects of surgery could not be concealed, and the results were imprecise due to the low number of events. New RCTs are needed to confirm these results and to compare CHIVA with approaches other than open surgery.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
5秒前
Yeses完成签到 ,获得积分10
5秒前
6秒前
啊啊啊啊发布了新的文献求助10
8秒前
pink发布了新的文献求助10
9秒前
9秒前
卡卡卡发布了新的文献求助10
9秒前
小明月发布了新的文献求助10
11秒前
13秒前
归尘应助啊啊啊啊采纳,获得10
15秒前
科研通AI2S应助啊啊啊啊采纳,获得10
15秒前
小小完成签到 ,获得积分10
19秒前
大力的图图应助小明月采纳,获得10
19秒前
FashionBoy应助科研通管家采纳,获得10
20秒前
小二郎应助科研通管家采纳,获得10
20秒前
彭于晏应助科研通管家采纳,获得10
20秒前
酷波er应助科研通管家采纳,获得10
20秒前
科目三应助科研通管家采纳,获得10
20秒前
20秒前
晨晨发布了新的文献求助10
24秒前
小枣完成签到 ,获得积分10
26秒前
27秒前
Lucas应助pink采纳,获得10
28秒前
六六发布了新的文献求助10
30秒前
小明月完成签到,获得积分10
33秒前
壳聚糖完成签到 ,获得积分10
35秒前
思源应助LLL采纳,获得10
36秒前
拟闲发布了新的文献求助10
37秒前
传奇3应助卡卡卡采纳,获得10
38秒前
GingerF应助Zbw采纳,获得50
38秒前
妩媚完成签到,获得积分10
40秒前
45秒前
Lucas应助妩媚采纳,获得10
45秒前
无敌大鸡腿完成签到,获得积分10
46秒前
46秒前
Muncy完成签到 ,获得积分10
48秒前
Viiigo完成签到,获得积分10
54秒前
活力的招牌完成签到 ,获得积分10
55秒前
Cc完成签到 ,获得积分10
58秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
HANDBOOK OF CHEMISTRY AND PHYSICS 106th edition 1000
ASPEN Adult Nutrition Support Core Curriculum, Fourth Edition 1000
AnnualResearch andConsultation Report of Panorama survey and Investment strategy onChinaIndustry 1000
Continuing Syntax 1000
Signals, Systems, and Signal Processing 610
Decentring Leadership 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6277260
求助须知:如何正确求助?哪些是违规求助? 8096857
关于积分的说明 16926547
捐赠科研通 5346365
什么是DOI,文献DOI怎么找? 2842392
邀请新用户注册赠送积分活动 1819644
关于科研通互助平台的介绍 1676797